

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

OTSUKA PHARMACEUTICAL CO., LTD., )  
)  
Plaintiff, )  
)  
v. ) C.A. No. \_\_\_\_\_  
)  
MSN LABORATORIES PRIVATE LIMITED )  
and MSN PHARMACEUTICALS INC. )  
)  
Defendants. )

**COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiff Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), by way of Complaint against Defendants MSN Laboratories Private Limited (“MSN Laboratories”) and MSN Pharmaceuticals Inc. (“MSN Pharmaceuticals”) (collectively, “MSN”), hereby alleges as follows:

**NATURE OF THE ACTION**

1. This is a civil action for patent infringement of U.S. Patent No. 8,501,730 (“the ’730 Patent”) and U.S. Patent No. 10,905,694 (“the ’694 Patent”) (collectively, the “Patents-in-Suit”) arising under the patent laws of the United States, 35 U.S.C. § 100 *et seq.*

2. This action arises out of MSN’s submission of an Abbreviated New Drug Application (“ANDA”) No. 216949 (“MSN’s ANDA”) under § 505(j) of the Federal Food, Drug and Cosmetic Act (“FDCA”), 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to commercially manufacture, use, offer for sell and sell in the United States, and/or import into the United States, generic versions of Otsuka’s SAMSCA® tolvaptan tablets (15 and 30 mg) (“MSN’s ANDA products”) prior to the expiration of the Patents-in-Suit.

### PARTIES

3. Otsuka is a corporation organized and existing under the laws of Japan with its corporate headquarters at 2-9 Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, 101-8535, Japan. Otsuka is engaged in the research, development, manufacture and sale of innovative pharmaceutical products.

4. On information and belief, Defendant MSN Laboratories is an Indian corporation, having its principal place of business at MSN House, C-24, Industrial Estate, Sanathnagar, Hyderabad-18, Telangana, India.

5. On information and belief, Defendant MSN Pharmaceuticals is a corporation organized under the laws of the State of Delaware, having its principal place of business at 20 Duke Road, Piscataway, New Jersey 08854.

6. On information and belief, MSN Pharmaceuticals is a wholly-owned subsidiary of MSN Laboratories.

7. On information and belief, MSN Pharmaceuticals and MSN Laboratories develop, manufacture, and/or distribute generic drugs for sale and use throughout the United States, including in Delaware.

8. On information and belief, MSN Pharmaceuticals and MSN Laboratories are agents of each other with respect to the development, regulatory approval, marketing, sale, and/or distribution of generic drug products. On information and belief, the acts of MSN Pharmaceuticals and MSN Laboratories complained of herein were done with the cooperation, participation, and assistance of, and at least in part for the benefit of, each other.

9. On information and belief, MSN Pharmaceuticals and MSN Laboratories have cooperated and assisted in the preparation and filing of MSN's ANDA for MSN's ANDA products,

and will be involved in the manufacture, importation, marketing, and sale of the drug that is the subject of MSN's ANDA if it is approved.

### **JURISDICTION AND VENUE**

10. This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

11. This Court has personal jurisdiction over MSN Pharmaceuticals because, on information and belief, MSN Pharmaceuticals is a corporation organized and existing under the laws of Delaware.

12. This Court has personal jurisdiction over MSN Laboratories because, *inter alia*, MSN Laboratories, itself and/or through its wholly-owned subsidiaries, has purposefully availed itself of the rights and benefits of Delaware law by engaging in systematic and continuous contacts with Delaware. On information and belief, MSN Laboratories directly or indirectly is in the business of developing, manufacturing, marketing, importing, offering to sell and selling pharmaceutical drug products, including generic drug products, throughout the United States, including in Delaware. Upon information and belief, MSN Laboratories derives substantial revenue from the sale of those products in Delaware and has availed itself of the privilege of conducting business within Delaware. Delaware would be a destination of MSN's ANDA products upon approval and marketing of the ANDA involved in this action. MSN Laboratories's filing of its ANDA constitutes a formal act that reliably indicates its plans to engage in marketing of the accused infringing ANDA products in Delaware.

13. Alternatively, assuming that the above facts do not establish personal jurisdiction over MSN Laboratories, this Court may exercise jurisdiction pursuant to Federal Rule of Civil Procedure 4(k)(2) because (a) Otsuka's claims arise under federal law; (b) MSN Laboratories is a

foreign defendant not subject to general personal jurisdiction in the courts of any state; and (c) MSN Laboratories has sufficient contacts with the United States as a whole, including but not limited to manufacturing and/or selling pharmaceutical products distributed throughout the United States, such that this Court's exercise of jurisdiction over MSN Laboratories satisfies due process.

14. This Court also has personal jurisdiction over MSN Laboratories because it has affirmatively availed itself of the jurisdiction of this Court through the assertion of counterclaims in suits brought in this District and/or by being sued in this District without challenging personal jurisdiction. *See, e.g., Vanda Pharmaceuticals, Inc. v. MSN Pharmaceuticals Inc. et al.*, Civil Action No. 19-926 (D. Del.); *Boehringer Ingelheim Pharmaceuticals Inc. et al., v. MSN Laboratories Private Ltd. et al.*, Civil Action No. 18-1785 (D. Del.); *Millennium Pharmaceuticals, Inc. v. MSN Laboratories Private Ltd. et al.*, Civil Action No. 16-1255 (D. Del.).

15. Venue is proper as to MSN in this judicial district under 28 U.S.C. §§ 1391 and 1400(b).

#### **OTSUKA'S SAMSCA®**

16. Otsuka is the holder of the New Drug Application ("NDA") No. 22-275 for SAMSCA® tablets in 15 and 30 mg dosage forms ("SAMSCA® tablets").

17. The FDA approved NDA No. 22-275 on May 19, 2009.

18. SAMSCA® is an oral medication used to treat hyponatremia (low blood sodium levels) in adults with conditions including congestive heart failure, cirrhosis and Syndrome of Inappropriate Antidiuretic Hormone.

**THE PATENTS-IN-SUIT**

19. The '730 Patent, entitled "Process for Preparing Benzazepine Compounds or Salts Thereof" was duly and legally issued on August 6, 2013. A true and correct copy of the '730 Patent is attached hereto as Exhibit A.

20. The '730 Patent claims compositions made by processes for preparing novel benzazepine compounds.

21. The '730 Patent is owned by Otsuka and is listed in *Approved Drug Products with Therapeutic Equivalents* (the "Orange Book") in connection with NDA No. 22-275 for SAMSCA® tablets.

22. According to the Orange Book, the '730 Patent expires on September 1, 2026.

23. The '694 Patent, entitled "Pharmaceutical Solid Preparation Comprising Benzazepines and Production Method Thereof," was duly and legally issued on February 2, 2021. A true and correct copy of the '694 Patent is attached hereto as Exhibit B.

24. The '694 Patent claims pharmaceutical solid preparations obtained by particular methods.

25. The '694 Patent is owned by Otsuka and is listed in the Orange Book in connection with NDA No. 22-275 for SAMSCA® tablets.

26. According to the Orange Book, the '694 Patent expires on April 7, 2030.

**MSN'S ANDA**

27. Upon information and belief, MSN submitted ANDA No. 216949 to the FDA under 21 U.S.C. § 355(j) seeking FDA approval to engage in the commercial manufacture, use, offer for sale or sale in the United States, or importation into the United States, of MSN's ANDA products, which are generic versions of SAMSCA®.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.